By Ben Glickman
Elutia is selling its orthobiologics business to Berkeley Biologics, a subsidiary of GNI Group. The company, which makes technologies meant to improve surgical outcomes, will receive $15 million in cash upfront, with potential earnout payments of up to $20 million over five years. Shares rise 50% to $1.86 after-hours.
60 Degrees…
Read the full article here
